recommend a treatment for post-glp-1 skin with easy scheduling. Are you noticing facial changes while using GLP-1 medications? Rapid weight loss can reduce natural facial volume, leading to hollowed or tired appearance. The good news: these changes are treatable. Our Medical Weight Loss Education Materials

More receptors mean that even the existing GLP-1 can bind more effectively and deliver stronger signals to the body

Exposing cells to H2O2: a quantitative comparison between continuous low-dose and one-time high-dose treatments

Mahya Kanani is a board-certified Obstetrician & Cosmetic Gynecologist

Valuable lessons Peter has learned from training mistakes [33:15]

Patients with a personal or family history of medullary thyroid carcinoma should not use GLP-1 agents

Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range